Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma

Journal of Investigative Dermatology

Volumn 114, Issue 4, 2000, Pages 637-642

  Blaheta, Hans Juergen ^a   Ellwanger, Ulf ^a   Schittek, Birgit ^a   Sotlar, Karl ^a   Maczey, Evelyn ^a   Breuninger, Helmut ^a   Thelen, Marcel H ^a   Bueltmann, Burkhard ^a   Rassner, Gernot ^a   Garbe, Claus ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Melanoma; Reverse transcription polymerase chain reaction; Sentinel lymph node; Staging

Indexed keywords

MONOPHENOL MONOOXYGENASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TUMOR CLASSIFICATION; TUMOR RECURRENCE;

EID: 0034001909     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2000.00925.x     Document Type: Article

References (47)

1. American Joint Committee on Cancer. Manual for Staging of Cancer. Philadelphia, PA: American Joint Committee on Cancer, 1992, pp. 143-148
2. Balch CM: The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol 6:163-172, 1988
3. Balch CM: Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 8:400-414, 1992
4. Balch CM, Soong S, Shaw HM, Urist MM, McCarthy SW. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch C (eds). Cutaneous Melanoma. Philadelphia: J.B. Lippincott, 1992, pp 165-187
5. Balch CM, Soong SJ, Bartolucci AA, et al: Efficacy of an elective regional lymph node dissection of 1-4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224:255-263, 1996
6. Bautista NC, Cohen S, Anders KH: Benign melanocytic nevus cells in axillary lymph nodes. A prospective incidence and immunohistochemical study with literature review. Am J Clin Pathol 102:102-108, 1994
7. Blaheta H-J, Schittek B, Breuninger H, et al: Lymph node micrometastases of cutaneous melanoma: Increased sensitivity of molecular diagnosis in comparison to immunohistochemistry. Int J Cancer 79:318-323, 1998
8. Blaheta H-J, Schittek B, Breuninger H, et al: Detection of melanoma micrometastasis in sentinel nodes by RT-PCR correlates with tumor thickness and is predictive for micrometastatic disease in the lymph node basin. Am J Surg Pathol 23:822-828, 1999
9. Breslow A: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172:902-908, 1970
10. Buttner P, Garbe C, Bertz J, et al: Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 75:2499-2506, 1995
11. Buzaid AC, Tinoco L, Ross MI, et al: Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 13:2104-2108, 1995
12. Buzaid AC, Ross MI, Balch CM, et al: Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 15:1039-1051, 1997
13. Campbell MJ, Gardner MJ. Calculating confidence intervals for some nonparametric analyses. In: Gardner MJ, Altmann DG (eds). Statistics with Confidence. London, British Medical Journal, 1989, pp 71-79
14. Carson KF, Wen DR, Li PX, Lana AMA, Bailly C, Morton DL, Cochran AJ: Nodal nevi and cutaneous melanomas. Am J Surg Pathol 20:834-840, 1996
15. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
16. Clark WHJ, From L, Bernardino EA, Mihm MC: The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29:705-727, 1969
17. Clark WHJ, Elder DE, Guerry D, et al: Model predicting survival in stage I melanoma based on tumor progression [see comments]. J Natl Cancer Inst 81:1893-1904, 1989
18. Cox D: Regression models and lifetables. J R Stat Soc B 34:187-201, 1972
19. Ercolani L, Florence B, Denaro M, Alexander M: Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. J Biol Chem 263:15335-15341, 1988
20. Gamel JW, George SL, Stanley WE, Seigler HF: Skin melanoma. Cured fraction and survival time as functions of thickness, site, histologic type, age, and sex. Cancer 72:1219-1223, 1993
21. Garbe C, Buttner P, Bertz J et al: Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer 75:2492-2498, 1995
22. Gershenwald JE, Colome MI, Lee JE, et al: Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16:2253-2260, 1998
23. Goydos JS, Ravikumar TS, Germino FJ, Yudd A, Bancila E: Minimally invasive staging of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction. J Am Coll Surg 182:182-190, 1998
24. Hsu SM, Raine L, Fanger H: The use of antiavidin antibody and avidin-biotinperoxidase complex in immunoperoxidase technics. Am J Clin Pathol 75:816-821, 1981
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
26. Kirkwood JM: Adjuvant IFNα2 therapy of melanoma. Lancet 351:1901-1903, 1998
27. Krag DN, Meijer SJ, Weaver DL, et al: Minimal-access surgery for staging of malignant melanoma. Arch Surg 130:654-658, 1995
28. Kwon BS, Haq AK, Pomerantz SH, Halaban R: Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus [published erratum appears in Proc Natl Acad Sci USA 1988 Sep; 85 (17): 6352]. Proc Natl Acad Sci USA 84:7473-7477, 1987
29. Kwon BS, Haq AK, Pomerantz SH, Halaban R: Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus [published erratum appears in Proc Natl Acad Sci USA 1988 Sep; 85 (17): 6352]. Proc Natl Acad Sci USA 84:7473-7477, 1987
30. Machin D, Campbell M, Fayers P, Pinol A: Comparing two survival curves. In: Machin D, Campbell M, Fayers P, Pinol A (eds). Sample Size Tables for Clinical Studies. London: Black well Science, 1997, pp 176-177
31. Miliotes G, Lyman GH, Cruse CW, et al: Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol 3:558-563, 1996
32. Mori M, Mimori K, Ueo H, et al: Clinical significance of molecular detection of carcinoma cells in lymph nodes and peripheral blood by reverse transcription polymerase chain reaction in patients with gastrointestinal or breast carcinomas. J Clin Oncol 16:128-132, 1998
33. Morton DL, Wen DR, Wong JH, et al: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392-399, 1992
34. Morton DL, Davtyan DG, Wanek LA, Foshag LJ, Cochran AJ: Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer 71:3737-3743, 1993
35. Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H: Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction: Comparison between MUC1 mRNA and keratin 19 mRNA amplification. Am J Pathol 148:649-656, 1996
36. Reintgen D: More rational and conservative surgical strategies for malignant melanoma using lymphatic mapping and sentinel node biopsy techniques. Curr Opin Oncol 8:152-158, 1996
37. Reintgen D, Cruse CW, Wells K et al: The orderly progression of melanoma nodal metastases. Ann Surg 220:759-767, 1994
38. Ross MI, Reintgen D, Balch CM: Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 9:219-223, 1993
39. Schoenfeld A, Luqmani Y, Sinnett HD, Shousha S, Coombes RC: Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients. Br J Cancer 74:1639-1642, 1996
40. Schwuerzer-Voit M, Proebstle TM, Sterry W: Identification of lymph node metastases by use of polymerase chain reaction (PCR) in melanoma patients. Eur J Cancer 32:264-268, 1996
41. Shivers SC, Wang XN, Li WG, et al: Molecular staging of malignant melanoma: Correlation with clinical outcome. JAMA 280:1410-1415, 1998
42. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338:1227-1229, 1991
43. Soong SJ, Shaw HM, Balch CM, McCarthy WH, Urist MM, Lee JY: Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg 16:191-195, 1992
44. Thompson JF, McCarthy WH, Bosch CM, et al: Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 5:255-260, 1995
45. Thorn M, Ponten F, Bergstrom R, Sparen P, Adami HO: Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst 86:761-769, 1994
46. Wang X, Heller R, VanVoorhis N, et al: Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 220:768-774, 1994
47. Worth AJ, Gallagher RP, Elwood JM, et al: Pathologic prognostic factors for cutaneous malignant melanoma: the Western Canada Melanoma Study. Int J Cancer 43:370-375, 1989